Tag: COH
Cochlear surpasses expectations
Earlier this month, hearing implant giant Cochlear surprised investors with a significant upgrade to revenue growth and earnings for the six months to December, along with higher guidance for the year to June 30. Today, it has followed up with the actual figures for the six months to December, along with a higher dividend.
Read MoreCompanies immune from rate rises: Sonic Healthcare, Cochlear, Transurban
Fund Manager Chris Pedersen discusses the RBA's rate hike, inflation, banks, dividend growth stocks, Sonic Healthcare, Transurban Group and Cochlear.
Read MoreCochlear anticipates robust performance for 2023-24
Hearing device manufacturer, Cochlear (ASX:COH), is poised for a strong performance in the fiscal year 2023-24, following a commendable performance until June.
Read MoreCorporate Chatter: TWE, COH, VCX
A veritable plethora of earnings reports through the ASX today, from which we have sifted those by Treasury Wine Estates, Cochlear and Vicinity Centres for your consideration.
Read MoreCochlear Hears from the ACCC on Oticon Bid
The ACCC has raised what it calls “significant preliminary competition concerns” with Cochlear’s proposed $170 million acquisition of Oticon Medical.
Read MoreNew FDA Hearing Aid Ruling May Impact Cochlear
In a move that could rattle the share price of Cochlear for a while, key US health regulators have cleared the way for hearing aids to be sold over the counter from the middle of October.
Read MoreElective Surgery Restrictions Hurt Cochlear
Cochlear has warned investors it expects the continuing restrictions on elective surgeries here and offshore will see slower growth in hearing implant sales for the year to June.
Read MoreCOH – Morgans rates the stock as Hold
While FY21 results were below consensus, they were in-line with Morgans expectations while guidance points to continued momentum. The Hold rating is unchanged and the target price increases to $214.5 from $201.1.
Read MoreCOH – Credit Suisse rates the stock as Neutral
The Neutral rating is unchanged and the target falls to $225 from $230.
Read MoreTurnaround in Place at Cochlear
Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read MoreImplant Maker Cochlear “Pleased With The Pace” Of Recovery
Hearing implant maker Cochlear has made an uncertain start to the 2020-21 financial year with first-quarter revenue down 6% because of the continuing impact of COVID-19.
Read MoreCOH – UBS rates the stock as Sell
UBS assumes a less favourable cost leverage scenario than the market, and consequently values Cochlear -10% below the current share price.
Read MoreCochlear Records $238m Loss On Virus, Litigation Hit
Cochlear’s annus horribilis caught up with it on Tuesday when the financial cost of the turbulent year was laid open for all to see.
Read MoreCochlear Warns On “Unchartered Territory” As Revenue Dives 60%
Despite raising more than $1 billion in new capital in March, Cochlear has provided a timely reminder that it is not out of the woods so far as the continuing impact of the COVID-19 pandemic.
Read MoreCOH – UBS rates the stock as Sell
UBS is not surprised by the company’s decision to raise up to $850m, considering the sudden deterioration in the operating environment and the likelihood of paying out $380m in penalties following the lost patent infringement case.
Read MoreCochlear Taps Investors To Battle Virus Turmoil
Hearing implant maker Cochlear has become the first major company to ask shareholders for more cash to bulk up its balance sheet against the expected ravages of the COVID-19 virus.
Read MoreCochlear Issues New Coronavirus Downgrade
On Friday’s dramatic slide and surge in the ASX, shares in hearing implant maker, Cochlear stood out with a leap of 21%. On Monday they dived up to 20% after the company issued its second earnings downgrade caused by the coronavirus, COVID-19 and warned that it is cutting all non-essential spending except for CAPEX. But it made clear staff numbers would not be cut.
Read MoreDo Less Risky Stock Market Exposures Really Exist?
With a sense of raw panic descending on global stock markets, the question is whether there are any truly safe havens in terms of remaining exposed to equities?
Read MoreCochlear Lifts Dividend Despite Flat Profit
Hearing aid group, Cochlear lifted dividend for the six months to December by 3% after revealing a lacklustre performance in the period.
Read MoreCOH – Morgans rates the stock as Hold
FY20 profit guidance is downgraded by up to -7% because of the impact of coronavirus in greater China. Management has not witnessed any impact outside of greater China and is not making any changes to the cost base.
Read MoreCochlear Cuts Guidance On Coronavirus Driven Slowdown
Hearing device maker Cochlear has revealed a sharp hit to earnings from the fallout from China’s continuing coronavirus crisis.
Read MoreCochlear Warns High Growth Days Are Over
Hearing implant maker Cochlear seems to be going ex-growth (or rather strong growth to a more mature style of earnings growth), judging by a downgrade delivered to yesterday’s annual meeting.
Read MoreEarnings Catchup: Newcrest, Cochlear, Domain, oOh! Media
Cochlear’s 2018-19 results topped market expectations, Newcrest has ridden the rising gold price higher, Domain has cut its full-year dividend while investors have given oOh! Media’s 2019 profit downgrade a big thumbs down.
Read MoreCOH – Citi rates the stock as Downgrade to Sell from Neutral
Citi expects net profit in FY19 of $275m, at the top end of guidance. The broker suspects market growth in North America will be lower than the prior corresponding period as Cochlear may have been more focused on protecting market share.
Read MoreCOH – Macquarie rates the stock as Underperform
Cochlear hosted an investor day on Friday at which no financial updates were provided. The company highlighted the opportunity presented by growth in adult uptake in developed markets along with new initiatives.
Read MoreCOH – Credit Suisse rates the stock as Underperform
The company has launched its new 3.0 Tesla MRI implant which allows users to undergo these MRIs without surgery. Credit Suisse expects the company will receive limited benefit from the new product in the second half.
Read MoreCOH – Deutsche Bank rates the stock as Sell
Deutsche Bank analysts, already among the more bearish when it comes to assessing the outlook for Cochlear, have returned from the 2019 American Audiology Annual meeting with the message that, yes indeed, competition is heating up in the global market for hearing aids.
Read MoreUS Competition Spooks Cochlear Investors
Cochlear shares dived more than 10% yesterday (Tuesday) after the company reported a higher interim result and dividend, but said it had lost market share in two of its biggest markets – the United States and Germany
Read MoreInvestors Deaf To Cochlear Growth Story
No thumbs up from investors yesterday to the 2017-18 annual result from Cochlear, the hearing implant pioneer.
Read MoreCochlear Lifts Dividend Despite Flat Result
Cochlear, the hearing implant maker, has underlined its confidence in the outlook by boosting interim dividend 8% despite what appeared to be a flat half-year profit.
Read MoreOptimistic Cochlear Raises Dividend
Cochlear shares are on track for their best day in 18 months, after the pioneering hearing implant maker boosted earnings by more than expected, boosted its final dividend by more than expected and foreshadowed further growth in 2018.
Read MoreCochlear H1 Profit Jumps 19%
There was something of a familiar story in yesterday’s half year result from hearing implant group, Cochlear (COH) – a nice rise in sales, a nice rise in profit and an even nice rise in interim dividend, and a reconfirmed full year guidance for a profit lift of around 10% to 20%.
Read MoreCochlear Tones Down Outlook
Shares in hearing implant maker Cochlear (COH) were sold off yesterday after the company warned that it expects its profit growth to slow this year after posting a 30% profit increase in the year to 30 June.
Read MoreCochlear Breaks $100
Shares in Cochlear (COH) cracked the $100 level yesterday, jumping more than 14% on the day, after it reported a 32% jump in interim profit and a tasty rise in half year dividend.
Read MoreHigh Expectations Hurt Cochlear
Greedy shareholders have given Cochlear (COH) a real whack yesterday for not making overly ambitious market estimates for earnings in the year to June.
Read MoreSmooth Leadership Transition At Cochlear
In a smooth transition, hearing implants maker Cochlear (COH) has found its new CEO from within its own ranks rather than look outside.
Read MoreCochlear Profits Rebound
The market noted the solid improvement in interim profit for hearing implants maker Cochlear (COH) in the six months to December, but also noted the board’s hesitation in restoring to the high level paid out a year earlier.
Read MoreCochlear Soars On Second Half Rebound
Shares in bionic ear maker, Cochlear (COH) more than doubled the 6% rise in the past year, thanks to a second half performance that confirmed the company is back on track after a rough first half of the 2013-14 financial year.
Read MoreApproval Delays Hit Cochlear
Cochlear (COH) was another company given a pounding yesterday from investors upset at what was in the interim profit report, even though much of the bad news was already in the market.
Read More
